"Tenofovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.
Descriptor ID |
D000068698
|
MeSH Number(s) |
D02.705.429.906 D03.633.100.759.138.881
|
Concept/Terms |
Tenofovir- Tenofovir
- 9-(2-Phosphonylmethoxypropyl)adenine
- 9-PMPA (tenofovir)
- 9-(2-Phosphonomethoxypropyl)adenine
|
Below are MeSH descriptors whose meaning is more general than "Tenofovir".
Below are MeSH descriptors whose meaning is more specific than "Tenofovir".
This graph shows the total number of publications written about "Tenofovir" by people in this website by year, and whether "Tenofovir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2014 | 0 | 1 | 1 |
2016 | 1 | 1 | 2 |
2020 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
2022 | 0 | 1 | 1 |
2023 | 0 | 2 | 2 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tenofovir" by people in Profiles.
-
Patterns of daily oral HIV PrEP adherence among people who inject drugs in Ukraine: an analysis of biomarkers. J Int AIDS Soc. 2024 Jul; 27 Suppl 3:e26319.
-
Low daily oral PrEP adherence and low validity of self-report in a randomized trial among PWID in Ukraine. Int J Drug Policy. 2024 Jan; 123:104284.
-
Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B. AIDS Res Ther. 2023 06 12; 20(1):37.
-
PrEP Use and Adherence among Transgender Persons in Chicago, IL (SHIPP Study, 2014-2018, USA). AIDS Behav. 2023 Mar; 27(3):901-908.
-
Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. Lancet HIV. 2021 03; 8(3):e130-e137.
-
Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi. J Acquir Immune Defic Syndr. 2021 01 01; 86(1):81-90.
-
Same-day prescribing of daily oral pre-exposure prophylaxis for HIV prevention. Lancet HIV. 2021 02; 8(2):e114-e120.
-
An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol. 2020 Sep; 55(9):811-823.
-
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy. Am J Gastroenterol. 2016 Dec; 111(12):1854-1856.
-
Preexposure Prophylaxis Awareness and Use in a Population-Based Sample of Young Black Men Who Have Sex With Men. JAMA Intern Med. 2016 Jan; 176(1):136-8.